Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JMT601 vs Rituximab and Cyclosporine in Primary Membranous Nephropathy
NCT07029139Phase 2Not yet recruiting
- Sponsor
- Shanghai Jinmante Biotechnology Co., Ltd.
- Start
- Jun 2025
- Primary completion
- Apr 2027
- Modality
- Fc-Fusion Proteins
01
Overview
A Phase 2 trial of JMT601 in primary membranous nephropathy (PMN), sponsored by Shanghai Jinmante Biotechnology Co., Ltd.. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
JMT601
03
Conditions
primary membranous nephropathy (PMN)
Beyond the preview
Go deeper on NCT07029139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07029139.